Fresenius Kabi and Portal Join Forces to Streamline Cell Therapy Development

Fresenius Kabi and Portal are collaborating with the aim of increasing the speed and reducing the cost of development of life-saving cell therapies.

The alliance brings together Fresenius Kabi’s Lovo Cell Processing System used to manufacture cell therapies and Portal's cell engineering technology to design and produce complex therapies from small initial quantities to larger volumes for clinical use.

“Our collaboration with Fresenius Kabi underscores our commitment to providing simple, scalable solutions that are compatible with today’s leading manufacturing equipment,” said Alec Barclay, COO at Portal. “Through this partnership, we are enabling researchers and clinicians to more quickly transition cell therapies from research bench to bedside.”

Cell therapy involves implanting healthy cells into the patient to replace or repair those that are damaged or diseased. It is used to treat a variety of diseases, including some forms of cancer, autoimmune disorders and others.

Portal’s proprietary MilliBooster technology uses gentle mechanical force to temporarily open cell membranes for genetic material to be inserted. Portal’s MilliBooster supports delivery of diverse genetic materials into cells, including CRISPR RNPs, mRNA, and circular RNA, as well as combinations of these materials.

Fresenius Kabi and Portal Join Forces to Accelerate Cell Therapy Development

Cells and Cargo Mechanical Disruption Intracellular Delivery

”Portal’s advanced cell engineering technology integrates effortlessly with our Lovo manufacturing system to deliver consistent, high-performance results¹,” said Saurabh Bhasin, Head of Portfolio, Cell & Gene Therapy Technologies & Contract Manufacturing at Fresenius Kabi. “This collaboration enhances the versatility of the Lovo system, providing cell therapy developers with an optimized path to clinical and commercial manufacturing.” Moving forward, the partnership will focus on further simplifying cell therapy development and production while unlocking the next generation of therapies.

Click here to download this White Paper.

Learn more about this exciting collaboration by visiting:

Portal

Chooselovo.com

This collaboration enhances the versatility of the Lovo system, providing cell therapy developers with an optimized path to clinical and commercial manufacturing.

Saurabh Bhasin - Head of Portfolio,

Cell & Gene Therapy Technologies & Contract Manufacturing, US

Download White Paper now

The Lovo Cell Processing System is for non–clinical laboratory and research use only. User must obtain appropriate regulatory clearance for clinical use.

Refer to the Lovo Cell Processing System Operator’s Manual or User’s Guide for a complete list of warnings and precautions associated with the use of these products.

¹ Fresenius Kabi AG. Scaling multiplexed cell engineering with Portal's MilliBooster and Fresenius Kabi's Lovo® Cell Processing System.

Trademarks referred to are property of their respective owners. 0103-LOVO-01-06/25